Douglas Sears
Encino, CANPI 1720062664
Payments from drug & device makers
Across 351 payments — averaging $56.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$5K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$4K
- AbbVie$2K
- Corium, LLC$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$894
- Otsuka America Pharmaceutical, Inc.$597
- plus $5K from 30 others
What the payments were for
- Consulting fees$10,70454%
- Speaking & faculty fees$1501%
- Food & beverage$8,72644%
- Education$1311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Zyprexa ZydisOlanzapine | 13 | $58,521 |
| Abilify MyciteAripiprazole | 25 | $42,362 |
| TrintellixVortioxetine Hydrobromide | 33 | $33,015 |
| VyvanseLisdexamfetamine Dimesylate | 29 | $17,496 |
| BelsomraSuvorexant | 28 | $15,474 |
| Dyanavel XrAmphetamine | 11 | $11,637 |
| Nurtec OdtRimegepant Sulfate | 11 | $10,788 |
| Lurasidone Hcl | 13 | $8,451 |
| Lisdexamfetamine Dimesylate | 34 | $8,405 |
| Atomoxetine Hcl | 29 | $5,122 |
| Paliperidone ErPaliperidone | 11 | $3,738 |
| Dexlansoprazole DrDexlansoprazole | 12 | $2,202 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 29 | $2,100 |
| Oxcarbazepine | 16 | $1,728 |
| KlonopinClonazepam | 12 | $1,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $335 | $50,51162 claims |
| Otsuka Pharmaceutical Development & Commercialization, Inc.Abilify Mycite | $4,003 | $42,36225 claims |
| MerckBelsomra | $22 | $15,47428 claims |
| Tris Pharma IncDyanavel Xr | $342 | $11,63711 claims |
| PfizerNurtec Odt | $62 | $10,78811 claims |
| Almatica Pharma LLCSertraline Hcl | $53 | $85466 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.